Takeda Pharmaceutical stock (JP3730800003): FY2026 profit surges 77.7%, but FY2027 guidance signals slowdown

Takeda Pharmaceutical reported a sharp 77.7% jump in net profit for fiscal 2026 to 191.8 billion yen, yet guided for mid-teens core earnings decline in FY2027 as generic competition pressures its ADHD franchise.

Takeda Pharmaceutical delivered stronger-than-expected fiscal 2026 results on May 13, 2026, with net profit attributable to owners surging 77.7% to 191.8 billion yen (approximately $1.22 billion), according to BioSpace as of May 13, 2026. The Japanese pharmaceutical giant's operating profit rose 19.3% to 408.8 billion yen, while core revenue edged down 1.6% to 4,505.7 billion yen, reflecting ongoing generic erosion in key markets.

The profit expansion was driven by lower research and development expenses, reduced amortization charges, and restructuring benefits rather than top-line growth. However, management's forward guidance tempered investor enthusiasm: Takeda expects core earnings per share to decline in the mid-teens percentage range during fiscal 2027, signaling headwinds ahead despite the current-year recovery.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Takeda Pharmaceutical Company Limited
• Sector/industry: Pharmaceuticals, specialty care, rare diseases
• Headquarters/country: Japan
• Core markets: North America, Europe, Japan, emerging markets
• Key revenue drivers: Gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines; legacy ADHD drug VYVANSE/ELVANSE
• Home exchange/listing venue: Tokyo Stock Exchange (ticker: 4502); ADR on OTC markets (TAK)
• Trading currency: Japanese yen (JPY); USD for ADR

Takeda Pharmaceutical: core business model

Takeda Pharmaceutical is one of the world's largest pharmaceutical companies by revenue, with a diversified portfolio spanning specialty care, rare diseases, plasma-derived therapies, oncology, and vaccines. The company operates across multiple therapeutic areas and geographic regions, with significant exposure to the North American market through its legacy ADHD franchise and more recent acquisitions in rare disease and plasma therapies. US investors can access Takeda shares via American Depositary Receipts (ADRs) trading on over-the-counter markets, making it accessible to retail portfolios seeking international pharmaceutical exposure.

Main revenue and product drivers for Takeda Pharmaceutical

Takeda's FY2026 revenue of 4,505.7 billion yen reflected a 1.7% year-on-year decline, with significant headwinds from its Neuroscience segment, which fell 26.8% to 414.3 billion yen. The steepest pressure came from VYVANSE/ELVANSE (lisdexamfetamine), the company's flagship ADHD treatment, which saw sales plummet 42.0% to 203.2 billion yen due to generic competition in the United States, according to SEC filings as of May 13, 2026. Offsetting this decline, Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, and Vaccines all posted growth, demonstrating the company's strategic pivot toward higher-margin specialty segments.

Core operating profit edged up to 1,172.5 billion yen despite the revenue decline, while core earnings per share increased 5.2% year-on-year at actual exchange rates and 3.1% at constant exchange rates. Adjusted free cash flow declined 11.0% to 684.5 billion yen as higher intangible investments and business payments offset strong underlying operating cash flow generation.

Conclusion

Takeda Pharmaceutical's fiscal 2026 results demonstrate a company in transition, with profit recovery driven by cost discipline and portfolio rebalancing rather than organic revenue growth. The sharp 42% decline in VYVANSE sales underscores the vulnerability of legacy franchises to generic competition, a challenge that will persist into fiscal 2027 as management guides for mid-teens core earnings contraction. For US investors, Takeda represents a diversified international pharmaceutical play with exposure to high-growth segments like rare diseases and plasma therapies, though near-term earnings momentum faces headwinds from patent cliff dynamics and currency fluctuations.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.